TY - JOUR
AU - K. Cherian
AU - K. Shinozuka
AU - B. J. Tabaac
AU - A. Arenas
AU - B. D. Beutler
AU - V. D. Evans
AU - C. Fasano
AU - O. S. Muir
A1 - 
AD - Department of Psychiatry & Behavioral Sciences, Stanford University, Palo Alto, CA.; Centre for Eudaimonia and Human Flourishing, University of Oxford, Oxford, United Kingdom.; Department of Psychiatry, University of Oxford, Oxford, United Kingdom.; University of Nevada, Reno School of Medicine, Reno, NV.; Department of Neurology, Carson Tahoe Health, Carson City, NV.; Department of Anesthesiology, University of Washington School of Medicine, Seattle, WA.; Keck School of Medicine, University of Southern California, Los Angeles, CA.; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY.; Teachers College, Columbia University, New York, NY.; Fermata Health, Brooklyn, NY; and.; Acacia Clinics, Sunnyvale, CA.
AN - 38518270
BT - Am J Ther
C5 - Opioids & Substance Use;
CP - 2
DA - Mar-Apr 01
DO - 10.1097/mjt.0000000000001723
DP - NLM
IS - 2
JF - Am J Ther
LA - eng
PY - 2024
SN - 1075-2765
SP - e133
EP - e140+
ST - Psychedelic Therapy: A Primer for Primary Care Clinicians-Ibogaine
T1 - Psychedelic Therapy: A Primer for Primary Care Clinicians-Ibogaine
T2 - Am J Ther
TI - Psychedelic Therapy: A Primer for Primary Care Clinicians-Ibogaine
U1 - Opioids & Substance Use;
U3 - 10.1097/mjt.0000000000001723
VL - 31
VO - 1075-2765
Y1 - 2024
ER -